Sanofi Ends Development of Two Phase III Drugs

Jun 03, 2013
By BioPharm International Editors

Sanofi has discontinued development of two investigational drugs in Phase III development, iniparib, a drug to treat non-small cell lung cancer, and otamixaban, an anticoagulant, based on recent clinical results. Sanofi will take an after-tax change of $285 million for iniparib.